Given the high expression of HDAC6 in ALL and the selectivity of WT161, our study elucidates the mechanisms of WT161 action and provides a foundation for its clinical development as a novel treatment for ALL. The gene discussed is HDAC6; the disease is acute lymphoblastic leukemia.